Laird Norton Wetherby Wealth Management’s Adaptive Biotechnologies ADPT Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,534	Closed	-$256K	–	929
2021 Q3	$256K	Hold	7,534	–	–	0.02%	770
2021 Q2	$308K	Buy	7,534 +556	+8%	+$21.6K	0.02%	709
2021 Q1	$281K	Sell	6,978 -2,151	-24%	-$116K	0.02%	621
2020 Q4	$540K	Buy	9,129 +859	+10%	+$44.3K	0.04%	439
2020 Q3	$402K	Sell	8,270 -2,584	-24%	-$109K	0.04%	429
2020 Q2	$525K	Sell	10,854 -3,877	-26%	-$141K	0.05%	347
2020 Q1	$409K	Buy	+14,731	New	+$411K	0.05%	371

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's ADPT Position: Q4 2021 in Review

Laird Norton Wetherby Wealth Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2021, closing a stake of 7,534 shares — an estimated $256K sold.

Laird Norton Wetherby Wealth Management first reported a position in ADPT in Q1 2020 and held it in 7 quarters. The position peaked at $540K in Q4 2020. 214 funds tracked by Wall St. Rank hold ADPT as of Q4 2021.

Laird Norton Wetherby Wealth Management reported no remaining Adaptive Biotechnologies position as of Q4 2021 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 7,534 Adaptive Biotechnologies shares in Q4 2021, an estimated $256K.
Laird Norton Wetherby Wealth Management first reported a position in Adaptive Biotechnologies in Q1 2020 and held it in 7 quarters.
Laird Norton Wetherby Wealth Management's Adaptive Biotechnologies position peaked at $540K in Q4 2020.
214 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2021.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2021, filed 14 Feb 2022.